Doxepin for insomnia: A systematic review of randomized placebo-controlled trials

Sleep Medicine Reviews

Volumn 19, Issue , 2015, Pages 75-83

  Yeung, Wing Fai ^a   Chung, Ka Fai ^a   Yung, Kam Ping ^a   Ng, Tommy Ho Yee ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antidepressants; Doxepin; Insomnia; Randomized controlled trials; Systematic review

Indexed keywords

DOXEPIN; PLACEBO; RAMELTEON; INDENE DERIVATIVE;

COCHRANE LIBRARY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; EFFECT SIZE; EMBASE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCREASED APPETITE; INSOMNIA; INSOMNIA SEVERITY INDEX; LATENT PERIOD; LEUKOPENIA; LOW DRUG DOSE; MEDLINE; PSYCINFO; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SLEEP; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ADOLESCENT; ADULT; AGED; DOSE RESPONSE; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXEPIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDENES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84920592096     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2014.06.001     Document Type: Review

References (28)

1. Ohayon M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002, 6:97-111.
2. Rodin S.S., Broch L., Buysse D., Dorsey C., Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. JClin Sleep Med 2008, 4:487-504.
3. Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A.N., et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. JPsychopharmacol 2010, 24:1577-1601.
4. Walsh J.K. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004, 27:1441-1442.
5. McCall C., McCall W.V. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?. Curr Psychiatry Rep 2012, 14:494-502.
6. Holshoe J.M. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009, 45:191-197.
7. Peretti S., Judge R., Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000, 403:17-25.
8. Food and Drug Administration FDA approved drug products 2013, Available at:. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
9. Weber J., Siddiqui M.A., Wagstaff A.J., McCormack P.L. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010, 24:713-720.
10. Becker P.M. Pharmacologic and nonpharmacologic treatments of insomnia. Neurol Clin 2005, 23:1149-1163.
11. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
12. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions 2008, Cochrane Collaboration, Wiley-Blackwell, Chichester, England, Hoboken, NJ.
13. Food and Drug Administration Drug approval package (application no.: 022036) 2010, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036s000_silenor_toc.cfm.
14. NCT00755495 Safety and efficacy of ramelteon and doxepin in subjects with chronic insomnia 2012, http://clinicaltrials.gov/show/NCT00755495.
15. Takeda A. Phase 2, double-blind, randomized, placebo-controlled, parallel-group, multicenter proof-of-concept study to evaluate the safety and efficacy of ramelteon taken in combination with doxepin for the treatment of subjects with chronic insomnia 2008, http://www.takeda.com/research/ct/pdf/report/29_Ramelteon_ClinicalTrialSynopsis_01-05-TL-375-067_NCT_00755495_en.pdf.
16. Krystal A.D., Durrence H.H., Scharf M., Jochelson P., Rogowski R., Ludington E., et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010, 33:1553-1561.
17. Krystal A.D., Lankford A., Durrence H.H., Ludington E., Jochelson P., Rogowski R., et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011, 34:1433-1442.
18. Lankford A., Rogowski R., Essink B., Ludington E., Heith Durrence H., Roth T. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012, 13:133-138.
19. Roth T., Rogowski R., Hull S., Schwartz H., Koshorek G., Corser B., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007, 30:1555-1561.
20. Roth T., Heith Durrence H., Jochelson P., Peterson G., Ludington E., Rogowski R., et al. Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 2010, 11:843-847.
21. Scharf M., Rogowski R., Hull S., Cohn M., Mayleben D., Feldman N., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. JClin Psychiatry 2008, 69:1557-1564.
22. Goldberg H.L., Finnerty R.J., Nathan L., Cole J.O. Doxepin in a single bedtime dose in psychoneurotic outpatients. Arch Gen Psychiatry 1974, 31:513-517.
23. Hajak G., Rodenbeck A., Voderholzer U., Riemann D., Cohrs S., Hohagen F., et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. JClin Psychiatry 2001, 62:453-463.
24. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
25. American Sleep Disorders Association The international classification of sleep disorders 1994, American Sleep Disorders Association, Rochester, Minnster, IL.
26. Okike K., Kocher M.S., Mehlman C.T., Bhandari M. Industry-sponsored research. Injury 2008, 39:666-680.
27. Buscemi N., Vandermeer B., Friesen C., Bialy L., Tubman M., Ospina M., et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. JGen Intern Med 2007, 22:1335-1350.
28. Huedo-Medina T.B., Kirsch I., Middlemass J., Klonizakis M., Siriwardena A.N. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012, 345:e8343.